FOLH1 and prostate cancer: In the work of Har et al. [44], the authors used the A10 aptamer and poly(D,L-lactic-co-glycolic acid (PLGA)-b-poly (ethylene glycol) (PEG) (PLGA-b-PEG) to develop nanoparticles to specifically deliver cisplatin to prostate cancer cells that express PSMA.